PBMs’ ‘Perverse Incentives’ Still Limiting Generics Access, AAM Report Reiterates
Supply Chain Middlemen Continue To Block Patient Access To Cheaper Generic Drugs
Generic medicines continue to be intentionally left off formulary tiers in favor of more expensive brand medications, according to a new report from the US Association for Accessible Medicines.
You may also be interested in...
Leonard Resignation Leaves AAM Looking For New Leadership
Dan Leonard has announced his resignation as president and CEO of the US Association for Accessible Medicines. He will be replaced on an interim basis by the group’s vice president for sciences and regulatory affairs, David Gaugh.
‘Middlemen’ Markups Are Penalizing Patients, Says AAM
The Association for Accessible Medicines has launched its Markup Madness campaign, which seeks to draw attention to the disparity in cost between generic drugs upon entry to the supply chain and when purchased in pharmacies.
Hyloris Lines Up Hectic Year Of Clinical Trials And Major US Launch
Hyloris has an eventful year ahead as it plans to conduct numerous trials for products in its ever-expanding pipeline and launch Maxigesic IV in the US.